AXLRx Book a callCommission
Twenty minutes with a consultant, before anything is commissioned.Book a scoping call →

Buyer's guide

Pharma commercial consulting: how to choose, and where AI fits.

A buyer's guide for commercial, access, medical and BD teams. What commercial consulting for pharma covers, the five ways teams buy it, and the questions that separate an answer you can act on from one you file.

Book a 20-min scoping callHow the engine works

What pharma commercial consulting covers

  1. Competitive positionWho holds which patient cohort, on what evidence, and where a new asset can win.
  2. Opinion leadersWhich clinicians shape practice in an indication and a market, and which are ready to engage.
  3. Trials and pipelineWhich programmes are closest to a readout, and what each is built to win on.
  4. Patients and market sizeHow many patients reach the pool a label can address, and where they leak.
  5. Access and priceHow payers and HTA bodies in each market will judge the asset, and what that does to price.
  6. Launch and fieldWhat must be true at launch, and how the field team is sized and deployed.

The five ways teams buy commercial answers

ModelWhat you get
Large strategy consultanciesBroad, senior and thorough. Weeks to months per question, priced for major decisions.
Specialist boutiquesDeep in a function or therapy area. Quality depends on the team assigned.
Syndicated reports and data platformsFast and consistent, but written for a category, not for your asset, and usually for major markets only.
Generic AI toolsInstant, but unsourced: a figure may be recalled rather than retrieved, and nothing is read by a pharma practitioner.
An AI consulting engine with consultantsThe AXLRx model: a method, live primary sources and a verification gate, read by a consultant. Built to your asset, in any market, in 72 hours.

Six questions to ask any provider

  1. Can every figure be traced?Ask for the source of three numbers in the sample. A PMID, trial ID or document you can open, not a footnote to a database.
  2. Is it built to your asset and label?A category view describes the market. An answer places your asset, comparators and label in it.
  3. Does it cover your market?Access in the Gulf, the UK and Germany runs on different rules. Ask how the provider handles SFDA and NUPCO, NICE, or AMNOG.
  4. Who reads it before it ships?An analysis a practitioner has not read is a draft.
  5. What do you receive?Working files - an editable model, a brief, a readout - rather than a slide of prose.
  6. How long does the answer take?Match the timeline to the decision it serves.

Commercial consulting for pharma, by question

ModuleCompetitive IntelligenceWho controls which cohort, and on what evidence?ModuleKOL MappingWhich experts actually move prescribing, and which are ready to engage?ModuleClinical Trial AnalyticsWho is running which trials, at what phase, on which endpoints?ModulePatient FlowHow many patients reach the eligible pool, and where do they leak?

Commercial consulting for pharma, by team

ForCommercial and launch strategyWhere can the asset win, how large is the pool it can reach, and what must be true at launch?ForMarket access and pricingHow will payers and HTA bodies judge the asset, and what does that do to price and uptake?ForMedical affairsWhich clinicians shape practice, which are ready to engage, and what does the trial landscape look like?ForBD, licensing and due diligenceIs the asset or indication commercially attractive, and what would it take to win?

Markets

United StatesUnited KingdomGCC (Gulf)GermanyFranceEvery published analysis

Pharma commercial consulting: frequently asked

What does a pharma commercial consulting firm do?

It answers the commercial questions behind launch, access and portfolio decisions: competitive position, opinion leaders, patient numbers, payer and HTA logic, pricing and field strategy.

How is AI changing pharma commercial consulting?

AI shortens the research and drafting that consume most of an engagement. The risk is unsourced output. AXLRx uses AI to retrieve, read and draft, and drops any figure it cannot find in the document it cites.

How do I choose a pharma commercial consulting partner?

Test traceability, fit to your asset, market coverage, who reviews the work, what files you receive and how long the answer takes. The six questions above are a working checklist.

Does AXLRx replace a strategy consultancy?

No. AXLRx answers a defined commercial question quickly and to a verified standard. When a decision needs a full engagement, MoatRx, the firm behind AXLRx, takes it on directly.

Which markets does AXLRx cover?

The library covers the US, UK, Gulf markets including Saudi Arabia and the UAE, Germany and France. Other markets are scoped on request.